Patients with rheumatoid arthritis who switched biologics incurred higher costs than patients who persisted on biologics. Etanercept appeared to be associated with the lowest costs.
Objectives: To estimate total costs among patients with rheumatoid arthritis (RA) who persisted on or switched from newly initiated biologic therapy.
Study Design: A retrospective claims database analysis.
Methods: This analysis included adults in the HealthCore Integrated Research Database with RA who initiated treatment with a biologic for RA (abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, or tocilizumab) between January 2009 and November 2014. Total healthcare costs (plan- and patient-paid) were estimated for 1 year post index. Treatment persistence was defined as no discontinuation (ie, no refill gap >45 days) and no biologic switch.
Results: Of 7468 patients, 45.2% persisted on the index biologic for at least 1 year without a refill gap and 16.7% switched to another biologic in the first year; other patients discontinued the index biologic (23.2%) or restarted after a refill gap (15.0%). Mean 1-year total healthcare costs per patient were $41,901 (95% CI, $40,855-$42,947) among persistent patients and $44,244 (95% CI, $40,820-$47,668) among switchers. In a multivariable analysis of all patients, switchers had 5% higher postindex costs on average than persistent patients (exp(β) = 1.05; 95% CI, 1.01-1.08), and etanercept had the lowest postindex costs (exp(β) ranged from 1.03 to 1.51 for other biologics relative to etanercept).
Conclusions: Patients with RA who switched biologic therapy incurred higher 1-year total postswitch healthcare costs compared with patients who were persistent on the index biologic. Healthcare costs were lowest for patients who started on etanercept, particularly those who persisted on etanercept.
Am J Manag Care. 2018;24(Spec Issue No. 8):SP338-SP345Takeaway Points
We examined treatment persistence (no refill gap >45 days) and total healthcare costs among nearly 7500 commercially insured patients in the United States who initiated treatment with a biologic for rheumatoid arthritis (abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, or tocilizumab) between January 2009 and November 2014. Mean 1-year total healthcare costs per patient were $41,901 among persistent patients and $44,244 among switchers. Switchers had 5% higher postindex costs on average than persistent patients.
Approximately 1.48 million adults in the United States have rheumatoid arthritis (RA),1 a chronic inflammatory joint disease leading to severe disability and premature mortality.2 Treatment guidelines for RA recommend methotrexate—or another conventional synthetic disease-modifying antirheumatic drug (DMARD), such as hydroxychloroquine, leflunomide, or sulfasalazine—alone for a patient with early RA and no prior DMARD therapy.3,4 Patients with an inadequate response to conventional synthetic DMARDs may benefit from initiation of biologic therapy, consisting of either a tumor necrosis factor inhibitor (TNFi), such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab, or a non-TNFi biologic, such as abatacept, rituximab, or tocilizumab.3,4
Many studies have examined treatment patterns for biologic therapy in clinical practice, such as persistence, switching to another biologic, restarting the same biologic after a gap in therapy, or discontinuation of biologic therapy.5-14 Nonpersistence on biologic therapy may occur due to medical reasons, such as inadequate response or medication intolerance,15-17 or due to payer policies or changes in coverage18 that lead to nonmedical switching to another biologic.19,20 Systematic reviews have concluded that interventions to improve adherence and persistence need to be identified6,8 and that large studies are needed to draw consistent conclusions about predictive factors for biologic treatment adherence and persistence.13
Several studies have compared medication costs or total healthcare costs across biologics21-33 or the cost-effectiveness of biologics34-45 in patients with RA. There is limited information comparing healthcare costs between patients with RA who switch biologics and those who persist on biologic therapy.46 The objective of this study was to estimate total healthcare costs among patients with RA in the first year after they initiated biologic therapy, according to biologic treatment patterns and the index biologic.
This was a retrospective cohort study of administrative claims data from the HealthCore Integrated Research Database (HIRD). HIRD contains a broad and geographically diverse spectrum of longitudinal claims data that represents the largest commercially insured population in the United States. HIRD is comparable with US Census data (American Community Survey) by age and gender, with slight underrepresentation of adults 65 years and older.47
To be included in the analysis, a patient needed to have at least 1 claim for a biologic of interest (abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, or tocilizumab), with an index date (the first biologic claim) between January 1, 2009, and November 30, 2014. Other key inclusion criteria were continuous enrollment in the health plan for at least 180 days preindex and at least 365 days post index, age of 18 to 63 years on the index date, at least 1 diagnosis for RA (based on International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes) in the preindex period, and an index claim after FDA approval for RA treatment for that biologic.
Patients could not receive more than 1 biologic of interest on the index date or any biologic dose greater than twice the approved maximum dose. To limit the analysis to patients newly initiating biologic therapy, patients were required to have no claim for any biologic of interest in the 180-day preindex period (ie, before the first claim for their index biologic). Patients were excluded from the analysis if during the preindex period they had any of the following conditions that are indications for at least 1 biologic of interest: psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, ulcerative colitis, Crohn disease, non-Hodgkin lymphoma, or chronic lymphocytic leukemia. Patients were excluded from the analysis if they had either no cost in the claims line for a biologic of interest or an inappropriate source of claims (eg, J-code for a self-administered biologic or a prescription claim for an intravenously administered biologic).
Study approval by an institutional review board and collection of informed consent from patients were not necessary for this retrospective claims-based analysis. No identifiable protected health information was collected or used in this study.
Patients were considered persistent on the index biologic if they had no refill gap of more than 45 days and did not switch to another biologic. This refill gap was selected based on the most common prescription period (30 days) plus 15 days, to avoid misclassification of patients who had a break in therapy but were persistent on treatment. The refill gap began at the end of the expected benefit of the prior dose. Thus, for a subcutaneous biologic, a refill gap started at the end of the reported days of supply in the most recent pharmacy claim. For an infusible biologic, the days of coverage for the most recent medical claim were calculated from the approved dosing schedule, and the refill gap started after the days of coverage ended. Patients were considered to have switched treatment if a nonindex biologic was initiated within 1 year post index. To be included in the postswitch analysis, patients needed to be continuously enrolled for at least 365 days after the switch. Patients with a refill gap of more than 45 days could either restart the same biologic after the treatment gap or discontinue the biologic without restarting the same biologic or switching to another biologic within 1 year post index.
Total healthcare costs were reported as the sum of plan-paid and patient-paid costs (ie, coinsurance, deductible, and co-payment) for inpatient hospitalizations, emergency department (ED) visits, outpatient services, and pharmacy costs. Costs for inpatient stays, ED visits, and outpatient services were identified from medical claims and could include costs incurred in these settings for infusion or administration of infusible biologics (eg, abatacept, infliximab, rituximab, and tocilizumab). Pharmacy costs included prescription fills from pharmacy claims, including subcutaneous biologics (eg, adalimumab, certolizumab pegol, etanercept, and golimumab) and medications for other conditions in pharmacy claims. Total healthcare costs and biologic costs were adjusted to 2015 US$ based on Consumer Price Index information provided by the Bureau of Labor Statistics.48
Analyses of 1-year total healthcare costs were performed post index among all patients and post switch among switchers. A nonparametric Wilcoxon test was conducted to compare postindex costs for persistent patients with postswitch costs for switchers. A multivariable analysis of factors associated with 1-year postindex total healthcare costs was performed using a generalized linear model with gamma distribution and log link. Covariates were treatment pattern, index biologic, age, sex, insurance plan type, geographic region, comorbidities, preindex total healthcare costs (all-cause and RA-related), and physician specialty. A separate multivariable analysis of factors associated with 1-year postswitch total healthcare costs used the same methods, but only in the patients who switched biologics.
Overall, 7468 eligible patients were identified from a sample of 105,325 patients who received at least 1 biologic during the identification period (Table 1). Patient eligibility criteria that resulted in attrition of more than 50% of possible patients were the absence of any diagnosis claim for RA in the preindex period (an inclusion criterion to identify use of the biologic for RA) and any biologic use in the preindex period (an exclusion criterion to identify new biologic use). The mean (SD) age of the study population was 48.8 (10.1) years, and 76.0% of patients were women. Other demographic characteristics, including health plan type, geographic region, and prescribing physician specialty, are summarized in Table 1.
During the 1-year postindex period, 45.2% of patients were persistent on the index biologic, 23.2% discontinued the index biologic, 16.7% switched to another biologic, and 15.0% restarted the index biologic after a refill gap of more than 45 days (P <.001 across treatment patterns). Statistically significant differences across the cohorts of patients by treatment pattern were observed for each of the demographic characteristics (Table 2).
Mean postindex total healthcare costs per switcher were $43,204 (95% CI, $41,572-$44,835). Mean 1-year total healthcare costs per patient were $41,901 (95% CI, $40,855-$42,947) for the first year post index among persistent patients and $44,244 (95% CI, $40,820-$47,668) for the first year post switch among switchers (P = .006) (Figure). Among persistent patients, mean 1-year total healthcare costs post index per patient ranged from $37,638 (95% CI, $36,783-$38,494) for etanercept to $73,202 (95% CI, $37,950-$108,455) for tocilizumab. Among switchers, mean 1-year postswitch total healthcare costs per patient ranged from $41,183 (95% CI, $38,807-$43,558) for etanercept to $57,080 (95% CI, $35,310-$78,849) for certolizumab pegol.
In the multivariable analysis of postindex 1-year total healthcare costs that adjusted for other factors (Table 3), patients who switched to another biologic had 5% higher costs, on average, than persistent patients (exp(β) = 1.05; 95% CI, 1.01-1.08; P = .015). Compared with etanercept, other biologics were associated with 3% to 51% higher postindex costs. Patients in the southern United States had 5% lower postindex costs than patients in the western United States. Compared with patients with RA without a comorbid condition, postindex costs were higher among patients with comorbid hypertension (11% higher; P <.001), asthma (10% higher; P <.001), neutropenia (27% higher; P = .010), or depression (15% higher; P <.001). Patients who were treated by a nonrheumatologist had 5% lower postindex costs than those who were treated by a rheumatologist.
A separate multivariable analysis was conducted in the subset of biologic switchers to examine baseline predictors for 1-year total healthcare costs after the switch (Table 4). After adjusting for other factors, starting on etanercept was associated with significantly lower postswitch costs than starting on abatacept (23% higher postswitch costs; P = .036), certolizumab pegol (39% higher; P = .025), or infliximab (21% higher; P = .009). Men had 20% higher postswitch costs than women (P <.001). Patients in the northeastern United States had 18% higher postswitch costs than patients in the western United States (P = .018). Patients treated by a nonrheumatologist had 11% higher postswitch costs than patients who were treated by a rheumatologist (P = .034).
In this analysis of treatment patterns and costs among nearly 7500 commercially insured patients with RA in the United States who initiated biologic therapy, 1 in 6 patients (16.7%) switched to a different biologic within the first year. Nearly half of the patients (45.2%) were persistent on their newly initiated biologic therapy without a refill gap of more than 45 days in the first year. For all index biologics combined, 1-year total healthcare costs were lower for the first year after treatment initiation among patients who were persistent on therapy compared with the 1-year total healthcare costs for the first year after patients switched biologic therapy. Patients who switch treatment may have higher costs both because they must visit a prescriber to switch the medication and because the new medication may require loading doses.
Previous studies examining biologic treatment persistence in patients with RA have used a variety of methods, which may explain why a systematic review of 52 studies reported rates of treatment persistence at 12 months ranging from 32% to 91%.8 Moreover, limited data are available specifically comparing costs between patients who were persistent on the index biologic therapy and those who switched biologic therapy. One study examined a smaller cohort of 474 patients with RA in Italy who received TNFi therapy with adalimumab, etanercept, or infliximab.46 Biologic use in the last 3 months of the first year post index was used to identify patients who were persistent (the same biologic at baseline) or switched (a different biologic at baseline). Rates of biologic switching in that study (18% for adalimumab, 15% for infliximab, and 11% for etanercept) were similar to the biologic switching rate in our study, despite the use of a different method to analyze switching, and treatment costs were higher for patients who switched biologics in the first year than for patients who did not switch (€12,710 vs €11,332). Notably, 47% of patients in the Italian cohort received another biologic in the preindex period. In our study, we included only patients with no biologic use in the preindex period to examine treatment patterns and costs in the first year after starting biologic therapy. Our analysis also examined treatment patterns and 1-year total healthcare costs associated with other biologics that are approved for the treatment of RA, including both TNFi and non-TNFi biologics.
Three studies compared costs between persistent and nonpersistent patients but did not examine costs separately among biologic switchers. In the first study, after initiation of a subcutaneous TNFi (adalimumab, etanercept, certolizumab pegol, or golimumab), 55% to 58% of patients were persistent on the TNFi at 12 months, and nonbiologic healthcare costs in the first year after initiation were significantly lower among persistent patients than nonpersistent patients.49 In the second study, patients who received TNFi therapy with adalimumab, etanercept, or infliximab reported lower costs among persistent patients than nonpersistent patients.50 In the third study, greater persistence on TNFi therapy with adalimumab, etanercept, or infliximab was associated with lower nonmedication costs.51 Because these studies did not examine costs among patients who switched to another biologic, it is not possible to compare the results of our study directly with those of the previous studies, but they support the finding in our study that treatment nonpersistence is associated with higher healthcare costs than treatment persistence in RA.
Among both persistent patients and switchers in this study, patients who initiated biologic therapy with etanercept had lower 1-year total healthcare costs than patients who initiated therapy with another biologic. Several previous studies have also found that in the treatment of RA or other inflammatory conditions, etanercept was associated with lower medication or total healthcare costs than other biologics, particularly when compared with infused biologics,21-30,43,52-57 but other studies have reported conflicting findings.11,32,33,58 These studies varied widely in the methods used to assess costs. Some studies examined only medication costs,11,26-30,43,52-56 whereas others examined total healthcare costs.21-25,57 Our study included all patient-paid and plan-paid amounts to examine total healthcare costs, inclusive of biologics, to assess the overall economic impact of initiating, persisting, and switching biologic treatment in RA.
This was a retrospective, claims-based analysis that did not randomize patients to treatment or stratify patients by baseline characteristics. Patients who switched biologic therapy were younger, more likely to be women, and more likely to be treated by a rheumatologist than the patients who were persistent on the index biologic. To adjust for these baseline differences, multivariable analyses of costs were conducted that included age, sex, and physician specialty among the variables. In the multivariable analysis of postindex costs among all patients, switching therapy was associated with significantly higher healthcare costs in the first year than persistence on the index biologic. Patients who initiated biologic therapy with etanercept continued to have lower healthcare costs in the first year compared with patients who initiated therapy with another biologic. Patients in the southern United States had lower healthcare costs than patients in the western United States, which may reflect differences in healthcare utilization in these regions. Patients treated by nonrheumatologists had lower healthcare costs than patients treated by rheumatologists, which may be attributable to increased referral of more severe cases from nonrheumatologists to rheumatologists.59 This hypothesis is supported by the finding that patients with greater comorbidity at baseline also had higher costs than patients with isolated RA in this study.
The multivariable analysis of 1-year total healthcare costs after switching biologic therapy was conducted in the subset of 964 patients who switched biologics and provided 12 additional months of data after the switch. Starting with etanercept as the index biologic was associated with significantly lower postswitch costs than starting biologic therapy with abatacept, certolizumab pegol, or infliximab. After adjustment for other variables, patients whose index biologic was adalimumab, golimumab, tocilizumab, or rituximab did not have significantly different postswitch costs compared with patients whose index biologic was etanercept. The total healthcare costs included the drug costs for biologic therapy after the switch but did not include costs before the switch date. This led to potentially confusing results for predicting postswitch costs based on the index biologic. In the multivariable analysis of postindex costs, rituximab and tocilizumab were associated with 51% and 17% higher postindex healthcare costs, respectively, than etanercept. In the multivariable analysis of postswitch costs, switching from rituximab or tocilizumab to another biologic was not associated with significantly higher costs after the switch as compared with switching from etanercept to another biologic. A likely explanation is that patients who initiated costly treatment with rituximab or tocilizumab switched to a less costly biologic, resulting in lower postswitch costs, but this study was not designed to examine costs across all possible combinations of biologic switching. Additionally, the small number of analyzed patients who switched from rituximab (n = 24) or tocilizumab (n = 9) to another biologic complicated the interpretation of these results. Several previous analyses also reported substantially greater use of etanercept, adalimumab, or infliximab compared with other biologics for the treatment of RA during the period covered by this analysis,11,33,54,58 so the smaller sample sizes for other biologics in this analysis were expected, which suggests that the results were applicable to typical clinical practice.
This analysis included only commercially insured patients, and the results might not be applicable to patients with Medicare or Medicaid coverage. Administrative claims data may not reflect treatment adherence, particularly if a subcutaneous biologic is dispensed but not administered.60 Claims data do not include information on the reason for a change in therapy, which may include both medical and nonmedical reasons. For example, formularies may influence biologic therapy choices for nonmedical reasons, but the administrative claims database did not include information about formularies. Among the medical reasons, disease progression was a likely contributor to switching therapy, but administrative claims also do not include direct measures of disease severity. Patients with more severe disease at baseline probably were more likely to fail the initial therapy and require a switch in biologic therapy post index. Thus, patient characteristics that were not available from the administrative claims database may have contributed to the higher costs among patients who switched biologic therapy. However, the significant association between switching biologic therapy and healthcare costs was maintained in generalized linear models that adjusted for other significant differences at baseline. Healthcare costs and treatment persistence were measured for 1 year, which is a standard approach for economic analyses of commercially insured patients, but differences in treatment persistence across biologics may not be evident until more than 12 months after initiation of therapy.49 Treatment persistence was based on a 45-day treatment gap from the end of the expected benefit for the prior dose, which accounted for different dosing schedules for biologic therapy. However, a 45-day gap could be more meaningful for a once-weekly medication (6 doses missed) than for a medication that is administered every 2 weeks (3 doses missed) or once monthly (1 dose missed). Treatment patterns after the initial switch were not analyzed among biologic switchers and may be an area for additional research. This analysis did not examine the effect of biologic dose escalation on costs; a patient whose dose was escalated during the first year but had no treatment gaps and did not switch to another biologic was considered persistent on the initial biologic. Previous studies have established that dose escalation differs among biologics,61-64 contributing to higher costs for biologics that require dose escalation.22,25,27
Patients who switched biologic therapy incurred higher 1-year total healthcare costs compared with patients who were persistent on the newly initiated biologic for at least 1 year. Of all biologics approved for RA, starting on etanercept and persisting on etanercept were associated with the lowest costs.
Jonathan Latham (PharmaScribe, LLC, on behalf of Amgen Inc) and Julie Wang (Amgen Inc) provided medical writing assistance. Pei Lin (HealthCore, Inc) assisted with statistical programming and creating variables. Mahdi Gharaibeh (Amgen Inc) critically reviewed the draft manuscript.Author Affiliations: HealthCore, Inc (TG, HT), Wilmington, DE; Amgen Inc (AM, BSS), Thousand Oaks, CA.
Source of Funding: This work was funded by Amgen Inc.
Author Disclosures: Mr Tan is an employee at HealthCore, Inc, which received a grant from Amgen to conduct this study, and Dr Gu was an employee at HealthCore at the time of this research. Dr Mutebi was an Amgen employee and stockholder at the time of this research. Dr Stolshek is an Amgen employee and stockholder. The authors report no other relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (TG, BSS, HT); acquisition of data (TG, HT); analysis and interpretation of data (TG, AM, BSS, HT); drafting of the manuscript (AM, BSS); critical revision of the manuscript for important intellectual content (TG, AM, BSS, HT); statistical analysis (TG, AM); obtaining funding (BSS); and supervision (HT).
Address Correspondence to: Tao Gu, PhD, HealthCore, Inc, 123 S Justison St, Ste 200, Wilmington, DE 19801-5134. Email: email@example.com.REFERENCES
1. Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. Arthritis Care Res (Hoboken). 2010;62(4):460-464. doi: 10.1002/acr.20041.
2. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative [correction in Ann Rheum Dis. 2010;69(10):1892). Ann Rheum Dis. 2010;69(9):1580-1588. doi: 10.1136/ard.2010.138461.
3. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1-26. doi: 10.1002/art.39480.
4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573.
5. Oei HB, Hooker RS, Cipher DJ, Reimold A. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(6):926-934.
6. Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther. 2010;10(9):1367-1378. doi: 10.1517/14712598.2010.510508.
7. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in Medicaid enrollees with rheumatoid arthritis. Value Health. 2010;13(6):805-812. doi: 10.1111/j.1524-4733.2010.00764.x.
8. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901-913. doi: 10.1016/j.clinthera.2011.06.001.
9. Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12:204. doi: 10.1186/1471-2474-12-204.
10. Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664-674. doi: 10.1007/s12325-012-0037-5.
11. Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm. 2014;20(12):1236-1244. doi: 10.18553/jmcp.2014.20.12.1236.
12. Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Adv Ther. 2014;31(4):410-425. doi: 10.1007/s12325-014-0110-3.
13. López-González R, León L, Loza E, Redondo M, Garcia de Yébenes MJ, Carmona L. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin Exp Rheumatol. 2015;33(4):559-569.
14. Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS. A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv Ther. 2016;33(4):626-642. doi: 10.1007/s12325-016-0312-y.
15. Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MÁ, Carmona L; BIOBADESER 2.0 Study Group. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis. 2012;71(3):382-385. doi: 10.1136/annrheumdis-2011-200302.
16. Markenson JA, Gibofsky A, Palmer WR, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol. 2011;38(7):1273-1281. doi: 10.3899/jrheum.101142.
17. Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36(10):2171-2177. doi: 10.3899/jrheum.090054.
18. Liang SY, Haas JS, Phillips KA. Medicare formulary coverage for top-selling biologics. Nat Biotechnol. 2009;27(12):1082-1084. doi: 10.1038/nbt1209-1082.
19. Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol. 2008;27(7):927-932. doi: 10.1007/s10067-008-0880-6.
20. Walsh CA, Minnock P, Slattery C, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;46(7):1148-1152. doi: 10.1093/rheumatology/kem074.
21. Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost—cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics. 2001;19(10):1051-1064.
22. Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2004;5(1):36. doi: 10.1186/1471-2474-5-36.
23. Weycker D, Yu EB, Woolley JM, Oster G. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged ≥65 years with rheumatoid arthritis. Clin Ther. 2005;27(5):646-656. doi: 10.1016/S0149-2918(05)00090-1.
24. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface. 2006;19(9):47-53.
25. Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm. 2010;67(15):1281-1287. doi: 10.2146/ajhp090487.
26. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67(9):1229-1234. doi: 10.1136/ard.2007.083675.
27. Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31(4):825-835. doi: 10.1016/j.clinthera.2009.04.002.
28. Carter CT, Changolkar AK, Scott McKenzie R. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ. 2012;15(2):332-339. doi: 10.3111/13696998.2011.649325.
29. Bonafede M, Joseph GJ, Shah N, Princic N, Harrison DJ. Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. Clinicoecon Outcomes Res. 2014;6:381-388. doi: 10.2147/CEOR.S61445.
30. Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans. J Med Econ. 2014;17(1):1-10. doi: 10.3111/13696998.2013.856314.
31. Nair K, Ghushchyan V, Naim A. Effectiveness and costs of TNF-alpha blocker use for patients with rheumatoid arthritis. Am Health Drug Benefits. 2013;6(2):126-136.
32. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin. 2007;23(8):1749-1759. doi: 10.1185/030079907X210615.
33. Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L. Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics. 2015;9:119-127. doi: 10.2147/BTT.S89286.
34. Chiou CF, Choi J, Reyes CM. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res. 2004;4(3):307-315. doi: 10.1586/14737188.8.131.527.
35. Merkesdal S, Ruof J, Mittendorf T, Zeidler H. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2004;5(9):1881-1886. doi: 10.1517/146565184.108.40.2061.
36. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol. 2009;36(1):16-26. doi: 10.3899/jrheum.080257.
37. Cimmino MA, Leardini G, Salaffi F, et al. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin Exp Rheumatol. 2011;29(4):633-641.
38. Curtis JR, Schabert VF, Yeaw J, et al. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. J Med Econ. 2014;17(8):555-566. doi: 10.3111/13696998.2014.914031.
39. Curtis JR, Schabert VF, Harrison DJ, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. 2014;36(7):996-1004. doi: 10.1016/j.clinthera.2014.05.062.
40. Meissner B, Trivedi D, You M, Rosenblatt L. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259-265. doi: 10.3111/13696998.2014.893241.
41. Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. J Med Econ. 2015;18(5):376-389. doi: 10.3111/13696998.2014.1001849.
42. Curtis JR, Chastek B, Becker L, et al. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. J Manag Care Spec Pharm. 2015;21(4):318-329. doi: 10.18553/jmcp.2015.21.4.318.
43. Gu T, Shah N, Deshpande G, Tang DH, Eisenberg DF, Harrison DJ. Biologic cost per effectively treated rheumatoid arthritis patient in a large managed care population: a retrospective cohort study. JHEOR. 2015;3(2):122-131.
44. Sauer BC, Teng C-C, He T, et al. Effectiveness and costs of biologics in veterans with rheumatoid arthritis. Am J Pharm Benefits. 2015;7(6):280-289.
45. Wu N, Bhurke S, Shah N, Harrison DJ. Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. Clinicoecon Outcomes Res. 2015;7:257-266. doi: 10.2147/CEOR.S83932.
46. Degli Esposti L, Favalli EG, Sangiorgi D, et al. Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. Clinicoecon Outcomes Res. 2017;9:9-17. doi: 10.2147/CEOR.S108730.
47. Wasser T, Wu B, Yˇcas JW, Tunceli O. Applying weighting methodologies to a commercial database to project US Census demographic data. Am J Accountable Care. 2015;3(3):33-38.
48. Archived Consumer Price Index detailed reports: 2015 detailed reports. US Department of Labor, Bureau of Labor Statistics website. bls.gov/cpi/tables/detailed-reports/home.htm. Published December 2015. Accessed May 22, 2017.
49. Dalén J, Svedbom A, Black CM, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016;36(7):987-995. doi: 10.1007/s00296-016-3423-5.
50. Degli Esposti L, Sangiorgi D, Perrone V, et al. Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study. Clinicoecon Outcomes Res. 2014;6:401-407. doi: 10.2147/CEOR.S66338.
51. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30(7):1375-1384. doi: 10.1016/S0149-2918(08)80063-X.
52. Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29(3):234-248. doi: 10.1007/s12325-012-0007-y.
53. Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15(2):264-275. doi: 10.3111/13696998.2011.644645.
54. Bonafede M, Joseph GJ, Princic N, Harrison DJ. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Med Econ. 2013;16(9):1120-1128. doi: 10.3111/13696998.2013.820192.
55. Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm. 2013;19(8):621-630. doi: 10.18553/jmcp.2013.19.8.621.
56. Sauer BC, Teng CC, He T, et al. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. J Med Econ. 2016;19(1):34-43. doi: 10.3111/13696998.2015.1086774.
57. Zeidler J, Mittendorf T, Müller R, von Kempis J. Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payer’s perspective. Health Econ Rev. 2012;2(1):20. doi: 10.1186/2191-1991-2-20.
58. Wu N, Lee YC, Shah N, Harrison DJ. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clin Ther. 2014;36(8):1231-1241, 1241.e1-e3. doi: 10.1016/j.clinthera.2014.06.014.
59. Referral, diagnosis and investigations. In: National Collaborating Centre for Chronic Conditions (UK). Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults. London, UK: Royal College of Physicians (UK); 2009.
60. Salaffi F, Carotti M, Di Carlo M, Farah S, Gutierrez M. Adherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritis. J Clin Rheumatol. 2015;21(8):419-425. doi: 10.1097/RHU.0000000000000320.
61. Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum. 2005;53(6):872-878. doi: 10.1002/art.21582.
62. Berger A, Edelsberg J, Li TT, Maclean JR, Oster G. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother. 2005;39(12):2021-2025. doi: 10.1345/aph.1G264.
63. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 2008;24(8):2229-2240. doi: 10.1185/03007990802229548.
64. Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ. 2012;15(4):635-643. doi: 10.3111/13696998.2012.667028.